|
Demographic, clinical, and immunological data in association with the resistance mutations in the PR gene of the HIV-1 isolates |
||
| Parameters |
PI associated resistance mutations |
|
|
|
||
| PI (+) N = 13 |
PI (-) N = 28 |
|
|
|
||
| Age of study entry (Mean+/-SD, years) |
10.2+/-5.2 |
10.6+/-2.7 |
| Length of treatment (Mean+/-SD, years) |
6.9+/-3.4 |
6.2+/-2.7 |
| NNRTI therapy |
9 (69.2%) |
12 (42.9%) |
| TAMs mutations |
10 (76.9%) |
18 (64.3%) |
| 3TC mutations |
9 (64.2%) * |
9 (32.1%) |
| NNRTI mutations |
6 (46.1%) |
12 (42.9%) |
| PI (secondary) |
10 (76.9%) *** |
15 (53.5%) |
| Clinical categories # |
||
| B |
6 (46.1) |
12/27 (44.4%) |
| C |
7 (53.9%) |
15/27 (55.6%) |
| Immune categories ## |
||
| 1 (no suppression) |
8 (61.5%) |
16 (57.1%) |
| 2–3 (moderate/severe) |
5 (28.5%) |
12 (42.9%) |
| PVL (n, %) |
||
| <10,000 |
1 (7.7%) ** |
14 (50.0%) |
| ≥ 10,000 |
12 (92.3%) |
14 (50.0%) |
|
Chi-square: * P < 0.02 ** P < 0.008 ***P < 0.0001 # Immune categories based on age-specific CD4+ T-lymphocyte count.22,23 ## B-moderately, C-severely symptomatic 22,23 | ||
Malhotra et al. AIDS Research and Therapy 2007 4:15 doi:10.1186/1742-6405-4-15 |
||